This inventor holds 3 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 2 EPO patents. Top assignees: Promethera Biosciences S.a./n.v., Promethera Therapeutics Sa. Active years: 2019-2022.
Company Filing History:
Years Active: 2019-2022
Title: Tuba Baran: Innovator in Liver Progenitor Cell Research
Introduction
Tuba Baran is a notable inventor based in Fontaine-l'Eveque, Belgium. He has made significant contributions to the field of regenerative medicine, particularly in the development of adult liver progenitor cells. With a total of 3 patents to his name, Baran's work is paving the way for advancements in liver disease treatment.
Latest Patents
Baran's latest patents focus on a method for producing adult liver progenitor cells, known as H2Stem Cells. These novel cells have been characterized based on a series of biological activities and markers. The methods developed for producing H2Stem Cells allow for the provision of these cells in the form of adherent cells and three-dimensional cell clusters in suspension. These cells can be differentiated into liver-specific cells that possess strong activities, making them suitable for treating liver diseases or for evaluating the efficacy, metabolism, and toxicity of various compounds.
Career Highlights
Throughout his career, Tuba Baran has worked with prominent companies in the biotechnology sector, including Promethera Biosciences and Promethera Therapeutics. His innovative research has garnered attention and respect within the scientific community, contributing to the advancement of therapeutic options for liver-related conditions.
Collaborations
Baran has collaborated with esteemed colleagues such as Etienne Sokal and Sarah Snykers, who have played a role in his research endeavors. Their combined expertise has further enhanced the impact of Baran's work in the field.
Conclusion
Tuba Baran's contributions to the development of adult liver progenitor cells represent a significant advancement in regenerative medicine. His innovative methods and collaborative efforts are crucial in the ongoing fight against liver diseases.